

BIMB SECURITIES RESEARCH MARKET INSIGHT

PP16795/03/2013(031743)

2QFY16 Caring Pharmacy

SELL ◆ ▶

Below Stock Data

Market Cap

Issued shares

Bloomberg Ticker

Still off-target

	· · · · · · · · · · · · · · · · · · ·		
	Caring MK	Altman Z-score	n.a.
	413.6	YTD price chg	-4.5%
	217.7	YTD KLCI chg	-3.6%
	2.14	Beta	0.8
	1.00	Major Shareholders	
ne	134.616	Motivasi Optima	50.4%

5-weekrange (H)	2.14	Beta	0.8
52-week range (L)	1.00	Major Shareholders	
3-mth avg daily volume	134,616	Motivasi Optima	50.4%
Free Float	31.6%	Perbadanan Nasional	12.8%
Shariah Compliant	Υ	Jitumaju SB	5.3%

	1mth	3mth	12mth
Absolute	(5.0)	(7.3)	61.3
vs. KLCI	(3.1)	(3.6)	76.5
Consensus	2016	2017	
Net Profit	12.8	13.4	
EPS (sen)	5.8	6.0	
Historical Price Ratio (x)	FY2013	FY2014	FY2015
Price Earnings	n.a.	28.4	20.4
Price to Book	n.a.	4.0	2.6

Financial Highlights	5				
FYE 30 May	2013	2014	2015	2016E	2017E
Turnover	301.4	338.3	367.0	400.8	440.4
EBIT	29.9	23.1	18.7	17.2	19.2
Pretax profit	29.8	22.9	18.5	16.9	18.9
Net Profit	20.6	15.1	12.9	11.9	13.3
EPS (sen)	9.4	6.9	5.9	5.5	6.1
PER (x)	20.1	27.4	32.1	34.8	31.1
DPS (sen)	0.0	1.5	1.5	1.5	1.5
Div. Yield (%)	0.0%	0.8%	0.8%	0.8%	0.8%
EBIT margin	9.9%	6.8%	5.1%	4.3%	4.4%
Pretax margin	9.9%	6.8%	5.0%	4.2%	4.3%
Effective tax rate	25.1%	28.6%	29.6%	29.0%	29.0%
ROE	41.2%	14.1%	11.0%	11.0%	14.9%
ROA	23.4%	8.0%	6.1%	6.0%	8.0%
Net Gearing (x)	net cash				
Growth ratios					
Turnover	21.4%	12.2%	8.5%	9.2%	9.9%
EBIT	10.8%	-22.6%	-19.0%	-8.2%	11.6%
Pretax profit	10.7%	-23.4%	-19.0%	-8.4%	11.6%
Net profit	12.5%	-26.4%	-14.9%	-7.5%	11.6%

-26.4%

-14.9%

-7.5%

11.6%

Research Team

EPS growth (%)

bimbresearch@bimbsec.com.my

12.5%

03-26131737

Price: Target Price:

Retain SELL.

RM1.90 (-38.4%) RM1.17

Caring's 1HFY16 net earnings of RM2.9m make up only 22% of both our full-year forecast and that of consensus. This reflects a -8.4% YoY change. Though not meeting projection, net earnings showed a YTD improvement of 11% on the back of a 7.6% YTD change in revenue from RM 177.4m to RM190.8m. The improved sales came from the same total number of 106 community pharmacies countrywide as in the 1QFY16. Following the poor 1H earnings, we have revised our FY16 and FY17 net earnings forecast to RM11.9m and RM13.3m respectively. Rolling forward our

valuation to FY17, our new target price comes to RM1.17.


QoQ. Net profit for the quarter showed QoQ improvement of 87.9% to RM1.9m from RM1m. This was at the back of a 6.2% QoQ change in revenue to RM98.3m. The improved performance was due to higher sales arising from Warehouse Sale launched during September 2015 and higher advertising and promotion income arising from marketing and promotional activities.

Margin under pressure. Caring's profit margin is expected to be under pressure due to the various negative headwinds such as rising cost of living, declining consumer sentiment to 63.8 points and longer gestation period for new pharmacy outlets (from 12-18 months to 18-24 months). All these negative economic factors are making consumers extra cautious in their spending behaviour.

Dividend. No dividend was declared during the current quarter.

Revised earnings. Alluding to the continued depressed state of the domestic economy which is fostering rising cost of living and declining consumer sentiment, we have revised our FY16 and FY17 net earnings forecasts to RM11.9m (-9%) and RM13.3m (-6%) respectively.

Valuation. Based on 3 year weighted average sector (retail and pharmaceutical) PER of 19.1x rolled over to FY17 EPS, we have derived a new target price of RM1.17. Maintain SELL.



Quarterly figures

dual tolly light to										
FYE 31 May (RMm)	2QFY15	3QFY15	4QFY15	1QFY16	2QFY16	QoQ Chg	YoY Chg	1HFY15	1HFY16	YTD Chg
Revenue	89.0	93.9	95.4	92.6	98.3	6.2%	10.4%	177.4	190.8	7.6%
EBIT	2.6	10.5	3.3	1.1	3.3	207.8%	26.4%	3.3	4.3	31.0%
Pretax profit	3.0	10.8	3.6	1.4	2.9	109.7%	-3.0%	4.0	4.2	5.1%
Taxation	(0.8)	(3.0)	(1.3)	(0.4)	(8.0)	109.9%	-2.9%	(1.1)	(1.2)	5.2%
Minority Interest	(0.0)	(0.2)	0.3	0.0	(0.1)	-522.9%	289.5%	(0.3)	(0.1)	-55.9%
Net Profit	2.1	7.6	2.6	1.0	1.9	87.9%	-8.4%	2.6	2.9	11.0%
EPS (sen)	1.0	3.5	1.2	0.5	0.9	87.9%	-8.4%	1.2	1.3	11.0%
Net gearing (x)	net cash	n.a	n.a	net cash	net cash	n.a				
EBIT margin (%)	2.9%	11.1%	3.5%	1.2%	3.3%	189.8%	14.5%	1.9%	2.3%	21.8%
PBT margin (%)	3.3%	11.5%	3.8%	1.5%	2.9%	97.5%	-12.2%	2.3%	2.2%	-2.3%
Net profit margin (%)	2.3%	8.1%	2.8%	1.1%	1.9%	77.0%	-17.0%	1.5%	1.5%	3.2%
Effective tax rate (%)	28.0%	28.0%	36.3%	28.0%	28.0%	0.1%	0.1%	28.0%	28.0%	0.1%

Source: BIMB Securities

DEFINITION OF RATINGS

BIMB Securities uses the following rating system:

STOCK RECOMMENDATION

BUY Total return (price appreciation plus dividend yield) is expected to exceed 10% in the next 12 months.

TRADING BUY Share price may exceed 15% over the next 3 months, however longer-term outlook remains uncertain.

NEUTRAL Share price may fall within the range of +/- 10% over the next 12 months

TAKE PROFIT Target price has been attained. Fundamentals remain intact. Look to accumulate at lower levels.

TRADING SELL Share price may fall by more than 15% in the next 3 months.

SELL Share price may fall by more than 10% over the next 12 months.

NOT RATED Stock is not within regular research coverage.

SECTOR RECOMMENDATION

OVERWEIGHT The Industry as defined by the analyst's coverage universe, is expected to outperform the relevant primary market

index over the next 12 months

NEUTRAL The Industry as defined by the analyst's coverage universe, is expected to perform in line with the relevant primary

market index over the next 12 months

UNDERWEIGHT The Industry as defined by the analyst's coverage universe, is expected to underperform the relevant primary market

index over the next 12 months

Applicability of ratings

The respective analyst maintains a coverage universe of stocks, the list of which may be adjusted according to needs. Investment ratings are only applicable to the stocks which form part of the coverage universe. Reports on companies which are not part of the coverage do not carry investment ratings as we do not actively follow developments in these companies.

Disclaimer

The investments discussed or recommended in this report may not be suitable for all investors. This report has been prepared for information purposes only and is not an offer to sell or a solicitation to buy any securities. The directors and employees of BIMB Securities Sdn Bhd may from time to time have a position in or either the securities mentioned herein. Members of the BIMB Group and their affiliates may provide services to any company and affiliates of such companies whose securities are mentioned herein. The information herein was obtained or derived from sources that we believe are reliable, but while all reasonable care has been taken to ensure that stated facts are accurate and opinions fair and reasonable, we do not represent that it is accurate or complete and it should not be relied upon as such. No liability can be accepted for any loss that may arise from the use of this report. All opinions and estimates included in this report constitute our judgements as of this date and are subject to change without notice. BIMB Securities Sdn Bhd accepts no liability for any direct, indirect or consequential loss arising from use of this report.

Published by



BIMB SECURITIES SDN BHD (290163-X)

A Participating Organisation of Bursa Malaysia Securities Berhad Level 32, Menara Multi Purpose, Capital Square,

No. 8 Jalan Munshi Abdullah,

50100 Kuala Lumpur

Tel: 03-2691 8887, Fax: 03-2691 1262

http://www.bimbsec.com.my

Head of Research